期刊
JOURNAL OF CLINICAL GASTROENTEROLOGY
卷 41, 期 4, 页码 345-351出版社
LIPPINCOTT WILLIAMS & WILKINS
DOI: 10.1097/01.mcg.0000225665.68920.df
关键词
chloride; chloride channels; constipation; functional bowel disorders; gastrointestinal motility; intestinal secretion; irritable bowel syndrome; lubiprostone
In January 2006 the Food and Drug Administration approved lubiprostone for the treatment of chronic constipation in men and women aged 18 and over. Lubiprostone is categorized as a prostone, a bicyclic fatty acid metabolite of prostaglandin E1. Lubiprostone activates a specific chloride channel (ClC-2) in the gastrointestinal (GI) tract to enhance intestinal fluid secretion, which increases GI transit and improves symptoms of constipation. This article reviews the role of chloride channels in the GI tract, describes the structure, function, and pharmacokinetics of lubiprostone, and discusses clinically important data on this new medication.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据